AR008375A1 - Compuestos fluorenonas alquiloxiaminas sustituidas y derivados de los mismos, procedimiento para la preparacion de compuestos utiles como intermediarios en la preparacion de los mismos y compuestos intermediarios. - Google Patents

Compuestos fluorenonas alquiloxiaminas sustituidas y derivados de los mismos, procedimiento para la preparacion de compuestos utiles como intermediarios en la preparacion de los mismos y compuestos intermediarios.

Info

Publication number
AR008375A1
AR008375A1 ARP970102266A ARP970102266A AR008375A1 AR 008375 A1 AR008375 A1 AR 008375A1 AR P970102266 A ARP970102266 A AR P970102266A AR P970102266 A ARP970102266 A AR P970102266A AR 008375 A1 AR008375 A1 AR 008375A1
Authority
AR
Argentina
Prior art keywords
compounds
preparation
substituted
alkyloxyamins
fluorenon
Prior art date
Application number
ARP970102266A
Other languages
English (en)
Original Assignee
Aventis Holdings Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27096988&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR008375(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aventis Holdings Inc filed Critical Aventis Holdings Inc
Publication of AR008375A1 publication Critical patent/AR008375A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
    • C07C217/14—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring
    • C07C217/24—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring being part of a condensed ring system containing rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/06—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
    • C07C2603/10—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings
    • C07C2603/12—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings only one five-membered ring
    • C07C2603/18—Fluorenes; Hydrogenated fluorenes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describe el uso de compuestos fluorenonas alquiloxiamino sustituídos y derivados de los mismos, caracterizado dicho uso para la preparacion de unmedicamento para el tratamiento de enfermedades mediadas por la proteína Kinasa C, poseyendo dichoscompuestos la formula general I donde: B, es S o NH; R4 esmetilo, etilo, n-propilo o ambos R4 pueden combinarse para dar pirrolidinilo, piperidinilo o morfolino; R5 es alquileno C1-5; V es hidrogeno, metoxi, etoxi,propoxi o butoxi; X es H ometoxi, etoxi, propoxi, fluoro, cloro o alquilamino C1-4; Y es H o NH2, NHR, NHCOR, donde R es alquilo C1-5 o fenilo; Z es H,alquilo C1-5, cloro, fluoro, BR5N(R4)2 donde R4, R5 y B son como se ha definidoantes; con la condicion de que: Z puedaestar prese nte en la posicion 1, 2, 3 o4 y, cuandoesté presente en la posicion 1, 2 o 4, substituya a Y, V o X, respectivamente; o una sal del mismo farmacéuticamente aceptable. También sedescriben nuevos compuestos con la condicion quecuando Z es BR5N (R4)2 entonces al menos uno de Y, V o X no sea hidrogeno o esté sustituído por Z.
ARP970102266A 1996-05-30 1997-05-28 Compuestos fluorenonas alquiloxiaminas sustituidas y derivados de los mismos, procedimiento para la preparacion de compuestos utiles como intermediarios en la preparacion de los mismos y compuestos intermediarios. AR008375A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65553796A 1996-05-30 1996-05-30
US65558496A 1996-05-30 1996-05-30

Publications (1)

Publication Number Publication Date
AR008375A1 true AR008375A1 (es) 2000-01-19

Family

ID=27096988

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP970102266A AR008375A1 (es) 1996-05-30 1997-05-28 Compuestos fluorenonas alquiloxiaminas sustituidas y derivados de los mismos, procedimiento para la preparacion de compuestos utiles como intermediarios en la preparacion de los mismos y compuestos intermediarios.

Country Status (18)

Country Link
EP (1) EP0906268B1 (es)
JP (1) JP3897363B2 (es)
CN (1) CN1160309C (es)
AR (1) AR008375A1 (es)
AT (1) ATE209626T1 (es)
AU (1) AU737073B2 (es)
BR (1) BR9709406B1 (es)
CA (1) CA2257136C (es)
DE (1) DE69708629T2 (es)
DK (1) DK0906268T3 (es)
ES (1) ES2170390T3 (es)
HK (1) HK1019147A1 (es)
HU (1) HUP9901621A3 (es)
IL (1) IL126873A (es)
NO (1) NO312457B1 (es)
NZ (1) NZ332597A (es)
PT (1) PT906268E (es)
WO (1) WO1997045397A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6103713A (en) * 1998-03-05 2000-08-15 Eli Lilly And Company Therapeutic treatment for autoimmune diseases
US6103712A (en) * 1998-03-05 2000-08-15 Eli Lilly And Company Therapeutic treatment for asthma
DE19908504C2 (de) * 1999-02-26 2003-04-30 Boehringer Ingelheim Pharma Großtechnisches Verfahren zur Herstellung von Derivaten der Biphenyl-2-carbonsäure durch Verseifen eines (2-Oxazolinyl)-2-biphenyl-Derivats mit Salzsäure
DE19917990A1 (de) * 1999-04-20 2000-11-02 Florian Lang Arzneimittel enthaltend Hemmstoffe der zellvolumenregulierten humanen Kinase h-sgk
DE60110802T2 (de) * 2000-08-18 2005-10-06 Agouron Pharmaceuticals, Inc., San Diego Heterozyklische-hydroximino-fluorene und ihre verwendung zur inhibierung von proteinkinasen
US7365193B2 (en) 2004-02-04 2008-04-29 Abbott Laboratories Amino-substituted tricyclic derivatives and methods of use
US20050171079A1 (en) * 2004-02-04 2005-08-04 Schrimpf Michael R. Amino-substituted tricyclic derivatives and methods of use
WO2011083483A2 (en) * 2010-01-11 2011-07-14 Healor Ltd. Method for treatment of inflammatory disease and disorder
CN103204781B (zh) * 2013-03-14 2015-04-01 武汉大学 2,7–二取代芴酮衍生物及其制备方法与应用
CN109053435A (zh) * 2018-08-03 2018-12-21 上海华堇生物技术有限责任公司 2,3-二甲氧基苯甲酰氯的制备方法
CN115590964A (zh) * 2022-09-14 2023-01-13 苏州大学（Cn） 蛋白激酶c抑制剂在制备抗肿瘤转移药物中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL33573A (en) * 1968-12-30 1973-10-25 Richardson Merrell Inc Bis-basic ethers and thioethers of fluorenone,fluorenol and fluorene
US5034384A (en) * 1990-08-01 1991-07-23 Merck & Co., Inc. 2-(9-fluorenonyl)-carbapenem antibacterial agents

Also Published As

Publication number Publication date
NO985577D0 (no) 1998-11-27
PT906268E (pt) 2002-05-31
DE69708629D1 (de) 2002-01-10
HUP9901621A3 (en) 2002-01-28
ES2170390T3 (es) 2002-08-01
JP3897363B2 (ja) 2007-03-22
HUP9901621A2 (hu) 1999-08-30
AU737073B2 (en) 2001-08-09
BR9709406A (pt) 1999-08-10
CA2257136A1 (en) 1997-12-04
NZ332597A (en) 2000-08-25
CN1160309C (zh) 2004-08-04
JP2000511528A (ja) 2000-09-05
IL126873A0 (en) 1999-09-22
NO985577L (no) 1999-01-27
NO312457B1 (no) 2002-05-13
EP0906268B1 (en) 2001-11-28
AU2736597A (en) 1998-01-05
IL126873A (en) 2005-09-25
HK1019147A1 (en) 2000-01-14
CA2257136C (en) 2004-07-20
WO1997045397A1 (en) 1997-12-04
CN1220660A (zh) 1999-06-23
BR9709406B1 (pt) 2009-05-05
DE69708629T2 (de) 2002-08-01
EP0906268A1 (en) 1999-04-07
DK0906268T3 (da) 2002-03-18
ATE209626T1 (de) 2001-12-15

Similar Documents

Publication Publication Date Title
YU40997A (sh) Novi oksadiazoli, postupci za njihovo pripremanje
AR029383A1 (es) Moleculas pequenas, los intermediarios para su sintesis, las composiciones farmaceuticas que las contienen y su uso para preparar un medicamento destinado al tratamiento o la profilaxis de enfermedades inflamatorias o mediadas por celulas inmunes
ZA988158B (en) Sulfinic acid derivatives and their preparation and use
PT98545A (pt) Processo para a preparacao de novos conjugados de antraciclinas utilizados como ligantes de agentes bioactivos
MY111142A (en) Antiarrhythmic agents
AR008375A1 (es) Compuestos fluorenonas alquiloxiaminas sustituidas y derivados de los mismos, procedimiento para la preparacion de compuestos utiles como intermediarios en la preparacion de los mismos y compuestos intermediarios.
ES2000346A6 (es) Un procedimiento para la preparacion de derivados de distamicina
TR199902897T2 (xx) S�v� benz-izo-kuinolin t�revleri.
TW360652B (en) Acryloyl substituted disstamycin derivatives, process for preparing them, and pharmaceutical composition comprising them
TW238304B (en) A process for the preparation of 1-substituted-5(4H)-tetrazolinones
SE8902273D0 (sv) Indenoindole compounds i
BG98644A (en) Piperazinyl (sulphonyl) amide derivatives of the camphor as oxytocin antagonists
ES2032217T3 (es) Nuevos derivados n-(23-vinblastinoil del acido 1-amino-metilfosfonico, sus procedimientos de preparacion y las composiciones farmaceuticas que los contienen.
DE68906826D1 (de) Phenothiazinderivate, deren herstellung und sie enthaltende pharmazeutische zusammensetzungen.
HUP0401831A2 (hu) Szubsztituált 1H-kinolin-2-on-vegyületek, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
ES2110454T3 (es) Compuestos de 6-oxo-azepinoindol, asi como procedimiento y productos intermedios para su preparacion y medicamentos que contienen estos compuestos.
ES8603396A1 (es) Procedimiento para la obtencion de nuevos derivados de benzoilurea y productos intermedios
ATE98961T1 (de) 1,8-benzonaphthyridinderivate und ihre herstellung.
HU900728D0 (en) Process for preparation of calcium antagonistics
MY107258A (en) 1-methoxypyrimidinyl-n-nitrophenyl-1h-1,2,4-triazole-3- sulphonamides, processes for their preparation and their use as herbicides.
DE3166674D1 (en) Substituted 3-aryl-2-cycloalkene-1-ones, process for their preparation and their parmaceutical use
FR2633622B1 (fr) Derives de sulfonyl indolizine, leur procede de preparation et leur utilisation comme intermediaires de synthese
AR005834A1 (es) Esteres de derivados de 3-hidroxipiperidinmetanol, un procedimiento para su preparacion, una composicion farmaceutica que los contiene, un procedimiento para preparar dicha composicion, un compuesto intermediario y un proceso para preparar un compuesto intermediario.
ES2006336A6 (es) Procedimiento de preparacion de nuevas acetamidas derivadas de la 2,3-dihidro-3-fenil-2-benzofuranona.
MX22863A (es) Procedimiento de preparacion de nuevos derivados sustituidos en posicion 15 de la 20,21-dinoreburnamenina.

Legal Events

Date Code Title Description
FG Grant, registration